Opexa Therapeutics, Inc.

Development of autologous cellular therapies for the treatment of multiple sclerosis, congestive heart failure and diabetes

Opexa Therapeutics (OPXA, name change from PharmaFrontiers in June 2006) is a biotechnology company investigating autologous cellular therapy to treat several major disease areas such as cardiac and pancreatic conditions and multiple sclerosis. The company holds the exclusive worldwide license of patents relating to the use of adult pluripotent stem cells derived from patients’ own circulating blood from the University of Chicago. The patents relate to stem cell technology discovered at The Department of Energy’s Office of Science Laboratory, Argonne National Lab.

David B. McWilliams, CEO C.W.
Lynne Hohlfeld, CFO
Jim C. Williams, PhD, COO
Donna R. Rill, VP of Operations

Gregory H. Bailey, MD
David Hung
David B. McWilliams
Lorin J. Randall
Michael S. Richman
Scott B. Seaman

Eliezer Huberman, PhD
Jingwu Zang, MD, PhD
Norman Barton, MD, PhD
Daniel R. Marshak, PhD
Shelly Heimfeld, PhD
Irun Cohen, MD

2635 N. Crescent Ridge Drive
The Woodlands, TX 77381
USA
Phone: +1-281-272-9331
Fax: +1-281-272-1088

The company develops and commercialises cell therapies to treat several major disease areas such as multiple sclerosis, rheumatoid arthritis, pancreatic and cardiac conditions. Its lead product, Tovaxin™, is a therapeutic vaccine for multiple sclerosis (MS) consisting of attenuated autoreactive T-cells. It induces the body’s immune system to attack the myelin reactive T-cells that are responsible for destroying the myelin sheath coating of the axons in the central nervous system. The company is also developing a novel diagnostic assay for MS.

Tovaxin™ is currently being evaluated in two Phase I/II clinical trials. Former trials showed that Tovaxin™ purges reactive T cells, thus stabilisating multiple sklerosis.